Experimental antibody targets deadly staph infections
NCT ID NCT02357966
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a lab-made antibody called 514G3 in 52 hospitalized adults with Staphylococcus aureus bloodstream infections. Participants received either a single dose of the antibody plus standard antibiotics or a placebo plus antibiotics. The main goals were to check safety and find the best dose. Results are not yet available, but the trial aims to see if adding this antibody can help clear the infection more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
514G3 (a human monoclonal antibody) given as a single intravenous dose alongside standard antibiotics
What this could lead to
If successful, this antibody could become an add-on treatment to help clear Staph bloodstream infections faster and more safely.
What could go wrong
This is an early-phase trial with only 52 participants, so results may not apply broadly. The antibody is experimental and may not improve outcomes over antibiotics alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAPHYLOCOCCUS AUREUS BACTEREMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
XBiotech Investigative Site
Columbus, Georgia, 31904, United States
-
XBiotech Investigative Site
Charlotte, North Carolina, 28203, United States